

# Pierre Baumann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5388593/publications.pdf>

Version: 2024-02-01

282  
papers

11,175  
citations

23567

58  
h-index

38395

95  
g-index

327  
all docs

327  
docs citations

327  
times ranked

6575  
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. <i>Pharmacopsychiatry</i> , 2018, 51, 9-62.	3.3	787
2	AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. <i>Pharmacopsychiatry</i> , 2011, 44, 195-235.	3.3	774
3	Interindividual Variability of the Clinical Pharmacokinetics of Methadone. <i>Clinical Pharmacokinetics</i> , 2002, 41, 1153-1193.	3.5	510
4	The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry. <i>Pharmacopsychiatry</i> , 2004, 37, 243-265.	3.3	453
5	Risperidone Versus Clozapine in Treatment-Resistant Chronic Schizophrenia: A Randomized Double-Blind Study. <i>American Journal of Psychiatry</i> , 1998, 155, 499-504.	7.2	266
6	Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 593-604.	4.7	208
7	Pharmacokinetic-Pharmacodynamic Relationship of the Selective Serotonin Reuptake Inhibitors???. <i>Clinical Pharmacokinetics</i> , 1996, 31, 444-469.	3.5	182
8	A Double-Blind, Placebo-Controlled Study of Citalopram With and Without Lithium in the Treatment of Therapy-Resistant Depressive Patients. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 307-314.	1.4	156
9	Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: Role of the variants of $\beta$ 1-acid glycoprotein. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 47, 338-346.	4.7	125
10	Analysis of Enantiomers of Citalopram and Its Demethylated Metabolites in Plasma of Depressive Patients Using Chiral Reverse-Phase Liquid Chromatography. <i>Therapeutic Drug Monitoring</i> , 1995, 17, 273-279.	2.0	125
11	Advantages and disadvantages of combination treatment with antipsychotics. <i>European Neuropsychopharmacology</i> , 2009, 19, 520-532.	0.7	125
12	Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. <i>International Clinical Psychopharmacology</i> , 2002, 17, 141-143.	1.7	116
13	ABCB1 and Cytochrome P450 Polymorphisms. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 319-326.	1.4	116
14	Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. <i>Pharmacogenetics and Genomics</i> , 1997, 7, 1-10.	5.7	112
15	Simultaneous Determination of Human Plasma Levels of Citalopram, Paroxetine, Sertraline, and Their Metabolites by Gas Chromatography–Mass Spectrometry. <i>Journal of Chromatographic Science</i> , 1998, 36, 365-371.	1.4	105
16	Nonresponse to Clozapine and Ultrarapid CYP1A2 Activity. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 214-219.	1.4	104
17	TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 162-174.	2.6	103
18	Cytochrome P450 2D6 Genotype and Methadone Steady-State Concentrations. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 229-234.	1.4	102

#	ARTICLE	IF	CITATIONS
19	Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. <i>Drug and Alcohol Dependence</i> , 2000, 61, 47-54.	3.2	101
20	The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 55-60.	5.7	98
21	Neuroendocrine Effects of a 20-mg Citalopram Infusion in Healthy Males A Placebo-Controlled Evaluation of Citalopram as 5-HT Function Probe. <i>Neuropsychopharmacology</i> , 1996, 14, 253-263.	5.4	97
22	Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 350-358.	4.7	94
23	Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. <i>Psychopharmacology</i> , 2005, 181, 751-760.	3.1	91
24	A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. <i>Journal of Affective Disorders</i> , 2014, 168, 269-275.	4.1	90
25	Oral administration of a low dose of midazolam (75µg) as an in vivo probe for CYP3A activity. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 237-46.	1.9	89
26	Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance. <i>Drug Safety</i> , 2006, 29, 735-768.	3.2	89
27	Comparative pharmacokinetics of selective serotonin reuptake inhibitors. <i>International Clinical Psychopharmacology</i> , 1995, 10, 15-22.	1.7	88
28	Pharmacology and pharmacokinetics of citalopram and other SSRIs. <i>International Clinical Psychopharmacology</i> , 1996, 11, 5-12.	1.7	88
29	Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , 1996, 50, 385-389.	1.9	87
30	Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 39-47.	5.7	87
31	Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: A pilot study. <i>Pharmacological Research</i> , 2008, 58, 344-347.	7.1	86
32	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	86
33	Treatment of Endogenous Depressions Resistant to Tricyclic Antidepressants or Related Drugs by Lithium Addition. Results of a Placebo-Controlled Double-Blind Study. <i>Pharmacopsychiatry</i> , 1989, 22, 183-187.	3.3	85
34	Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 403-410.	2.1	85
35	Increased Clozapine Plasma Concentrations and Side Effects Induced by Smoking Cessation in 2 CYP1A2 Genotyped Patients. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 539-543.	2.0	84
36	Stereoselective Biotransformation of the Selective Serotonin Reuptake Inhibitor Citalopram and Its Demethylated Metabolites by Monoamine Oxidases in Human Liver. <i>Biochemical Pharmacology</i> , 1998, 56, 15-23.	4.4	83

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 231-6.	1.9	82
38	Paroxetine Increases Steady-State Concentrations of (R)-Methadone in CYP2D6 Extensive but Not Poor Metabolizers. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 211-215.	1.4	81
39	Methadone Maintenance Treatment and St. John's Wort. <i>Pharmacopsychiatry</i> , 2003, 36, 35-37.	3.3	80
40	Enantiomers' potential in psychopharmacology—a critical analysis with special emphasis on the antidepressant escitalopram. <i>European Neuropsychopharmacology</i> , 2002, 12, 433-444.	0.7	79
41	Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry. <i>Biomedical Applications</i> , 1996, 682, 265-272.	1.7	76
42	Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients. <i>Biomedical Applications</i> , 1996, 686, 51-63.	1.7	76
43	Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC. <i>Chirality</i> , 1995, 7, 389-395.	2.6	75
44	Probable Metabolic Interaction Between Methadone and Fluvoxamine in Addict Patients. <i>Therapeutic Drug Monitoring</i> , 1994, 16, 42-45.	2.0	74
45	The Effect of Fluoxetine on the Pharmacokinetics and Safety of Risperidone in Psychotic Patients. <i>Pharmacopsychiatry</i> , 2002, 35, 50-56.	3.3	73
46	Cytochrome P-450 activities in human and rat brain microsomes. <i>Brain Research</i> , 2000, 855, 235-243.	2.2	72
47	Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. <i>Brain Research</i> , 1999, 831, 229-236.	2.2	71
48	Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. <i>European Journal of Clinical Pharmacology</i> , 2005, 60, 865-873.	1.9	70
49	Dextromethorphan and Mephenytoin Phenotyping of Patients Treated with Thioridazine or Amitriptyline. <i>Therapeutic Drug Monitoring</i> , 1992, 14, 1-8.	2.0	68
50	Fluvoxamine and Fluoxetine Do Not Interact in the Same Way With the Metabolism of the Enantiomers of Methadone. <i>Journal of Clinical Psychopharmacology</i> , 1997, 17, 113-117.	1.4	68
51	Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. <i>European Journal of Clinical Pharmacology</i> , 1990, 39, 613-614.	1.9	66
52	Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. <i>Pharmacological Research</i> , 1995, 31, 347-353.	7.1	66
53	Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. <i>Psychopharmacology</i> , 1996, 128, 421-425.	3.1	66
54	Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography. <i>Biomedical Applications</i> , 1998, 719, 234-238.	1.7	65

#	ARTICLE	IF	CITATIONS
55	Caffeine consumption in hospitalized psychiatric patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1996, 246, 83-92.	3.2	62
56	Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 322-331.	4.7	61
57	Methadone Blood Concentrations Are Decreased by the Administration of Abacavir Plus Amprenavir. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 553-555.	2.0	59
58	Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine After Multiple Doses of Fluoxetine in Cytochrome P4502D6 Poor and Extensive Metabolizers. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 330-334.	1.4	57
59	Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 55-63.	4.7	57
60	Amitriptyline Pharmacokinetics and Clinical Response: II. Metabolic Polymorphism Assessed by Hydroxylation of Debrisoquine and Mephenytoin. <i>International Clinical Psychopharmacology</i> , 1986, 1, 102-112.	1.7	55
61	High Interindividual Variability of Methadone Enantiomer Blood Levels to Dose Ratios. <i>Archives of General Psychiatry</i> , 1998, 55, 89.	12.3	55
62	Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, S1-207.	2.1	55
63	Identification of a novel splice-site mutation in the CYP1A2 gene. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 341-344.	2.4	53
64	Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. <i>European Neuropsychopharmacology</i> , 2002, 12, 255-260.	0.7	51
65	Efavirenz decreases methadone blood concentrations. <i>Aids</i> , 2000, 14, 1291.	2.2	50
66	The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. <i>Dialogues in Clinical Neuroscience</i> , 2005, 7, 231-247.	3.7	50
67	Interindividual differences in the binding of antidepressives to plasma proteins: the role of the variants of alpha1-acid glycoprotein. <i>European Journal of Clinical Pharmacology</i> , 1985, 27, 661-666.	1.9	49
68	Steady State Plasma Levels of the Enantiomers of Trimipramine and of Its Metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-Phenotyped Patients. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 209-214.	2.0	49
69	Inflammation-induced changes in expression and glycosylation of genetic variants of $\alpha$ 1-acid glycoprotein. Studies with human sera, primary cultures of human hepatocytes and transgenic mice. <i>Biochemical Journal</i> , 1991, 276, 343-347.	3.7	48
70	Search for biological correlates of depression and mechanisms of action of antidepressant treatment modalities. Do neuropeptides play a role?. <i>Physiology and Behavior</i> , 2007, 92, 226-231.	2.1	48
71	Steady-State Concentrations of Mirtazapine, N-Desmethylmirtazapine, 8-Hydroxymirtazapine and their Enantiomers in Relation to Cytochrome P450 2D6 Genotype, Age and Smoking Behaviour. <i>Clinical Pharmacokinetics</i> , 2009, 48, 63-70.	3.5	46
72	Isoelectric focusing of alpha-1 acid glycoprotein (orosomuroid) in immobilized pH-gradients with 8M urea: Detection of its desialylated variants using an alkaline phosphatase-linked secondary antibody system. <i>Electrophoresis</i> , 1988, 9, 650-654.	2.4	45

#	ARTICLE	IF	CITATIONS
73	GC and GC-MS procedures for simultaneous phenotyping with dextromethorphan and mephenytoin. <i>Clinica Chimica Acta</i> , 1988, 171, 211-222.	1.1	44
74	Lithium Augmentation in Depressive Patients Not Responding to Selective Serotonin Reuptake Inhibitors. <i>Pharmacopsychiatry</i> , 2001, 34, 119-127.	3.3	43
75	Use of Plasma Level Monitoring of Antidepressants in Clinical Practice. <i>Pharmacopsychiatry</i> , 1991, 24, 190-195.	3.3	42
76	Orosomucoid System: 17 Additional Orosomucoid Variants and Proposal for a New Nomenclature. <i>Vox Sanguinis</i> , 1993, 64, 47-55.	1.5	42
77	Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. <i>Drug and Alcohol Dependence</i> , 2003, 69, 205-211.	3.2	42
78	Therapeutic Monitoring of Psychotropic Drugs. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 167-170.	2.0	42
79	Determination of picogram levels of midazolam, and 1- and 4-hydroxymidazolam in human plasma by gas chromatography-“negative chemical ionization”-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 802, 339-345.	2.3	40
80	Use of transgenic mice for the characterization of human alpha 1-acid glycoprotein (orosomucoid) variants. <i>Human Genetics</i> , 1989, 84, 89-91.	3.8	38
81	Determination of plasma levels of citalopram and its demethylated and deaminated metabolites by gas chromatography and gas chromatography-“mass spectrometry. <i>Biomedical Applications</i> , 1993, 616, 221-228.	1.7	38
82	Determination of the enantiomers of thioridazine, thioridazine 2-sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma. <i>Biomedical Applications</i> , 1995, 669, 271-279.	1.7	38
83	Pharmacokinetic Fluvoxamine - Clomipramine Interaction with Favorable Therapeutic Consequences in Therapy-resistant Depressive Patient. <i>Pharmacopsychiatry</i> , 1996, 29, 108-110.	3.3	38
84	Cytochrome <i>P450</i> and <i>ABC1</i> genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. <i>Journal of Psychopharmacology</i> , 2011, 25, 896-907.	4.0	38
85	Psychotropic Drug Prescription in a Psychiatric University Hospital. <i>Pharmacopsychiatry</i> , 1999, 32, 29-37.	3.3	37
86	Chirality in the New Generation of Antidepressants. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 366-374.	2.0	35
87	Drug refractory epilepsy in brain damage: effect of dextromethorphan on EEG in four patients.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994, 57, 333-339.	1.9	34
88	Stereoselective Metabolism of Citalopram in Plasma and Cerebrospinal Fluid of Depressive Patients. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 283-290.	1.4	34
89	Treatment-resistant schizophrenia: clinical experience with new antipsychotics. <i>European Neuropsychopharmacology</i> , 1996, 6, 21-25.	0.7	33
90	Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 1051-1061.	2.1	33

#	ARTICLE	IF	CITATIONS
91	Increased trimipramine plasma levels during fluvoxamine comedication. <i>European Neuropsychopharmacology</i> , 1994, 4, 15-20.	0.7	32
92	Fluoxetine Addition to Methadone in Addicts: Pharmacokinetic Aspects. <i>Therapeutic Drug Monitoring</i> , 1996, 18, 570-572.	2.0	32
93	Variations in relative concentrations of variants of human $\beta$ 1-acid glycoprotein after acute-phase conditions. <i>Clinica Chimica Acta</i> , 1991, 203, 379-385.	1.1	31
94	THE ASSOCIATION CARBAMAZEPINE-MIANSERIN IN OPIATE WITHDRAWAL: A DOUBLE BLIND PILOT STUDY VERSUS CLONIDINE. <i>Pharmacological Research</i> , 1997, 35, 451-456.	7.1	31
95	Clinical Outcome after Trimipramine in Patients with Delusional Depression - a Pilot Study. <i>Pharmacopsychiatry</i> , 2003, 36, 12-17.	3.3	31
96	Routine Therapeutic Drug Monitoring in Patients Treated with 10-360 mg/day Citalopram. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 600-608.	2.0	31
97	Orosomucoid (alpha-1 acid glycoprotein) phenotyping by use of immobilized pH gradients with 8M urea and immunoblotting. <i>Human Genetics</i> , 1988, 80, 183-185.	3.8	30
98	Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study. <i>European Journal of Clinical Pharmacology</i> , 1993, 44, 403-405.	1.9	30
99	CYP3A activity measured by the midazolam test is not related to 3435 C>T polymorphism in the multiple drug resistance transporter gene. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 255-260.	5.7	30
100	Prevalence of substance use in a Swiss psychiatric hospital: Interview reports and urine screening. <i>Addictive Behaviors</i> , 2006, 31, 1252-1258.	3.0	30
101	A double-blind double-dummy study of citalopram comparing infusion versus oral administration. <i>Journal of Affective Disorders</i> , 1998, 49, 203-210.	4.1	29
102	Pharmacokinetic Drug Interaction Potential of Risperidone With Cytochrome P450 Isozymes as Assessed by the Dextromethorphan, the Caffeine, and the Mephenytoin Test. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 228-231.	2.0	29
103	An alternative to interruption of treatment in recurrent clozapine-induced severe neutropenia. <i>British Journal of Psychiatry</i> , 2001, 179, 180-180.	2.8	29
104	Evaluation of the levels of free and total amitriptyline and metabolites in the plasma and brain of the rat after long-term administration of doses used in receptor studies. <i>Psychopharmacology</i> , 1984, 84, 489-495.	3.1	28
105	Increase of alpha 1 acid glycoprotein after treatment with amitriptyline.. <i>British Journal of Clinical Pharmacology</i> , 1982, 14, 102-103.	2.4	27
106	Marked Increase of Venlafaxine Enantiomer Concentrations as a Consequence of Metabolic Interactions: A Case Report. <i>Pharmacopsychiatry</i> , 2000, 33, 112-115.	3.3	27
107	In vitro biotransformation of the selective serotonin reuptake inhibitor citalopram, its enantiomers and demethylated metabolites by monoamine oxidase in rat and human brain preparations. <i>Molecular Psychiatry</i> , 2002, 7, 181-188.	7.9	27
108	Major depressive disorder in the general hospital: adaptation of clinical practice guidelines. <i>General Hospital Psychiatry</i> , 2003, 25, 185-193.	2.4	27

#	ARTICLE	IF	CITATIONS
109	Quetiapine and Norquetiapine in Plasma and Cerebrospinal Fluid of Schizophrenic Patients Treated With Quetiapine. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 496-503.	1.4	27
110	Effects of Carbamazepine Coadministration on Plasma Concentrations of the Enantiomers of Mianserin and of its Metabolites. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 166-170.	2.0	27
111	Multicenter Study on the Clinical Effectiveness, Pharmacokinetics, and Pharmacogenetics of Mirtazapine in Depression. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 622-629.	1.4	26
112	Enantiomeric antidepressant drugs should be considered on individual merit. <i>Human Psychopharmacology</i> , 2001, 16, S85-S92.	1.5	25
113	Therapeutic Drug Monitoring for Drugs Used in the Treatment of Substance-Related Disorders: Literature Review Using a Therapeutic Drug Monitoring Appropriateness Rating Scale. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 561-572.	2.0	25
114	Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1988, 337, 220-4.	3.0	24
115	Orosomuroid System: 17 Additional Orosomuroid Variants and Proposal for a New Nomenclature. <i>Vox Sanguinis</i> , 1993, 64, 47-55.	1.5	24
116	Determination of the Enantiomers of Mianserin and its Metabolites in Plasma by Capillary Electrophoresis After Liquid-Liquid Extraction and On-Column Sample Preconcentration. <i>Journal of Chromatographic Science</i> , 1997, 35, 315-320.	1.4	24
117	Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. <i>Journal of Psychopharmacology</i> , 2004, 18, 559-566.	4.0	24
118	Therapeutic Monitoring of Antidepressants in the Era of Pharmacogenetics Studies. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 152-155.	2.0	24
119	Relationships between brain concentrations of desipramine and paradoxical sleep inhibition in the rat. <i>Journal of Neural Transmission</i> , 1983, 56, 105-116.	2.8	23
120	Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 79-102.	2.0	23
121	Care of depression in the elderly. <i>International Clinical Psychopharmacology</i> , 1998, 13, S35-S44.	1.7	22
122	Binding of Amitriptyline to $\alpha$ 1-Acid Glycoprotein and its Variants. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 40, 767-770.	2.4	22
123	Steady State Concentrations of the Enantiomers of Mianserin and Desmethylmianserin in Poor and in Homozygous and Heterozygous Extensive Metabolizers of Debrisoquine. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 7-13.	2.0	22
124	Inappropriate secretion of antidiuretic hormone and SSRIs. <i>British Journal of Psychiatry</i> , 1996, 169, 524-525.	2.8	21
125	The Effect of the N-methyl-D-aspartate Receptor Antagonist Dextromethorphan on Perioperative Brain Injury in Children Undergoing Cardiac Surgery with Cardiopulmonary Bypass: Results of a Pilot Study. <i>Neuropediatrics</i> , 1997, 28, 191-197.	0.6	21
126	Ultrarapid Metabolism of Clomipramine in a Therapy-Resistant Depressive Patient, as Confirmed by CYP2D6 Genotyping. <i>Pharmacopsychiatry</i> , 1998, 31, 72-72.	3.3	21



#	ARTICLE	IF	CITATIONS
127	Value and Actuality of the Prescription Information for Therapeutic Drug Monitoring of Psychopharmaceuticals: A Comparison with the Medico-Scientific Evidence. <i>Pharmacopsychiatry</i> , 2007, 40, 121-127.	3.3	21
128	Drug-induced Pisa syndrome under quetiapine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 1286-1287.	4.8	21
129	The analysis of free tryptophan in human blood with the ultrafiltrator: A comparison with other methods. <i>Clinica Chimica Acta</i> , 1977, 76, 223-231.	1.1	20
130	Amitriptyline Pharmacokinetics and Clinical Response: 1. Free and Total Plasma Amitriptyline and Nortriptyline. <i>International Clinical Psychopharmacology</i> , 1986, 1, 89-101.	1.7	20
131	Plasma Levels of Trimipramine and Metabolites in Four Patients. <i>Therapeutic Drug Monitoring</i> , 1992, 14, 380-385.	2.0	20
132	Artifacts in the analysis of thioridazine and other neuroleptics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1993, 11, 451-457.	2.8	20
133	Determination of the enantiomers of mianserin, desmethylmianserin, and 8-hydroxymianserin in the plasma and urine of mianserin-treated patients. <i>Chirality</i> , 1994, 6, 555-563.	2.6	20
134	Citalopram-lithium combination treatment of elderly depressed patients: A pilot study. <i>International Journal of Geriatric Psychiatry</i> , 1995, 10, 281-287.	2.7	20
135	Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 952-956.	4.8	20
136	Determination of free and bound plasma tryptophan by ultrafiltration. <i>Clinica Chimica Acta</i> , 1974, 51, 35-40.	1.1	19
137	Lithium concentrations in saliva, plasma and red blood cells of patients given lithium acetate. <i>Acta Psychiatrica Scandinavica</i> , 1978, 58, 67-79.	4.5	19
138	Oral and intravenous methadone use: some clinical and pharmacokinetic aspects. <i>Drug and Alcohol Dependence</i> , 1999, 55, 137-143.	3.2	19
139	Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. <i>International Journal of Neuropsychopharmacology</i> , 2000, 3, 55-60.	2.1	19
140	Light-Induced Racemization. <i>Therapeutic Drug Monitoring</i> , 1991, 13, 356-362.	2.0	18
141	N-methylation of maprotiline in debrisoquine/mephenitoin-phenotyped depressive patients. <i>Biochemical Pharmacology</i> , 1985, 34, 409-410.	4.4	17
142	Adverse Drug Reactions Following Nonresponse in a Depressed Patient with CYP2D6 Deficiency and Low CYP 3A4/5 Activity. <i>Pharmacopsychiatry</i> , 2006, 39, 150-152.	3.3	17
143	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain) Tj ETQq1 1 0.784314 rgBT /Overlock <i>Psychiatry</i> , 2021, 22, 561-628.	2.6	17
144	Serotonin Syndrome After Small Doses of Citalopram or Sertraline. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 713-714.	1.4	17

#	ARTICLE	IF	CITATIONS
145	On the Relationship between Free Plasma and Saliva Amitriptyline and Nortriptyline. <i>International Pharmacopsychiatry</i> , 1982, 17, 136-146.	0.4	16
146	Influence of Quinidine on the Pharmacokinetics of Trimipramine and on Its Effect on the Waking EEG of Healthy Volunteers. <i>Neuropsychobiology</i> , 1992, 25, 214-220.	1.9	16
147	Cardiac Left Bundle Branch Block and Pancytopenia in Anorexia Nervosa: Higher Risk with Mirtazapine and Pantoprazole? Case Report. <i>Pharmacopsychiatry</i> , 2009, 42, 79-81.	3.3	16
148	Psychiatric comorbidity and additional abuse of drugs in maintenance treatment with<scp>l</scp>- and<scp>d</scp>, <scp>l</scp>-methadone. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 390-399.	2.6	16
149	Olanzapine for mixed episodes of bipolar disorder. <i>Journal of Psychopharmacology</i> , 1999, 13, 198-198.	4.0	15
150	Identification of N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine and bufotenin by cellulose TLC. <i>Journal of Chromatography A</i> , 1973, 86, 269-273.	3.7	14
151	Neuroendocrine effects of chronic neuroleptic therapy in male psychiatric patients. <i>Psychoneuroendocrinology</i> , 1978, 3, 245-252.	2.7	14
152	Pharmacodynamic and pharmacokinetic interactions of selective serotonin re-uptake inhibiting antidepressants (SSRIs) with other psychotropic drugs. <i>Nordic Journal of Psychiatry</i> , 1993, 47, 13-19.	1.3	14
153	High Dose of Depot Risperidone in a Nonresponder Schizophrenic Patient. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 673-674.	1.4	14
154	Epileptiform Seizure After Sertraline Treatment in an Adolescent Experiencing Obsessive-Compulsive Disorder and Presenting a Rare Pharmacogenetic Status. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 679-681.	1.4	14
155	Therapeutic drug monitoring of antidepressants " clinical aspects. , 2007, , 261-267.		14
156	Separation of indole derivatives and catecholamines by thin-layer chromatography. <i>Journal of Chromatography A</i> , 1971, 59, 463-466.	3.7	13
157	The serotonin paradox: Negative symptoms and SSRI augmentation. <i>International Journal of Psychiatry in Clinical Practice</i> , 1998, 2, 19-26.	2.4	13
158	In vitro metabolism of citalopram by monoamine oxidase B in human blood. <i>European Neuropsychopharmacology</i> , 2001, 11, 75-78.	0.7	13
159	Death following acute poisoning by moclobemide. <i>Forensic Science International</i> , 2004, 140, 101-107.	2.2	13
160	A proposal for a psychopharmacology "pharmacotherapy catalogue of learning objectives and a curriculum in Europe. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 29-38.	2.6	13
161	Age and adverse drug reactions from psychopharmacological treatment: Data from the AMSP drug surveillance programme in Switzerland. <i>Swiss Medical Weekly</i> , 2013, 143, w13772.	1.6	13
162	Inappropriate antidiuretic hormone secretion and rhabdomyolysis associated with citalopram. <i>Therapie</i> , 2000, 55, 651-2.	1.0	13

#	ARTICLE	IF	CITATIONS
163	Microprocedure to determine the polymorphic forms of acid Î±1-glycoprotein in plasma. Biomedical Applications, 1982, 229, 319-325.	1.7	12
164	Reversible neutropenia during a cold: possible involvement of risperidone? A case report. European Neuropsychopharmacology, 1995, 5, 1-2.	0.7	12
165	Interaction of psychotropic drugs with monoamine oxidase in rat brain. Journal of Pharmacy and Pharmacology, 2010, 53, 1125-1130.	2.4	12
166	Relationship between Plasma-levels of Chlorpromazine and Effects on EEG and Evoked Potentials in Healthy Volunteers. Pharmacopsychiatry, 1981, 14, 199-204.	3.3	11
167	French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs. Fundamental and Clinical Pharmacology, 2010, 24, 377-384.	1.9	11
168	Age at the time of onset of psychosis: A marker of specific needs rather than a determinant of outcome?. European Psychiatry, 2017, 45, 20-26.	0.2	10
169	Micro-determination of SiO <sub>2</sub> , TiO <sub>2</sub> , total iron (Fe <sub>2</sub> O <sub>3</sub> ), P <sub>2</sub> O <sub>5</sub> and F in silicates by automatic solution photometry. Fresenius Zeitschrift für Analytische Chemie, 1975, 277, 359-368.	0.8	9
170	Non-Response to Antidepressants: Risk Factors and Therapeutic Possibilities. Pharmacopsychiatry, 1988, 21, 285-287.	3.3	9
171	Alopecia and mood stabilizers: Two case reports. European Archives of Psychiatry and Clinical Neuroscience, 1992, 242, 85-88.	3.2	9
172	Determination of trimipramine and its demethylated and hydroxylated metabolites in plasma by gas chromatography-mass spectrometry.. Biomedical Applications, 1994, 652, 97-103.	1.7	9
173	Clozapine is more efficacious for tongue dystonia than olanzapine. Psychopharmacology, 2002, 162, 89-89.	3.1	9
174	Increased creatinine kinase and rhabdomyolysis in anorexia nervosa. International Journal of Eating Disorders, 2008, 41, 766-767.	4.0	9
175	Cognitive Efficacy of Quetiapine in Early-Onset First-Episode Psychosis: A 12-Week Open Label Trial. Psychiatric Quarterly, 2012, 83, 311-324.	2.1	9
176	Pharmacokinetic Consequences of a Citalopram Treatment Discontinuation. Therapeutic Drug Monitoring, 1999, 21, 263.	2.0	9
177	Long-term treatment of depression. International Clinical Psychopharmacology, 1997, 12, 77-80.	1.7	8
178	Influence of Progesterone on Norepinephrine Metabolism of the Rat Brain in Connection with Amphetamine and Stress. Neuroendocrinology, 1971, 7, 16-24.	2.5	7
179	Quantitative determination of indolic compounds in the rat brain using p-dimethylaminocinnamaldehyde as reagent. Journal of Chromatography A, 1975, 109, 313-324.	3.7	7
180	High-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiency. International Journal of Psychiatry in Clinical Practice, 2004, 8, 191-195.	2.4	7

#	ARTICLE	IF	CITATIONS
181	New Aspects in Research on Blood Levels and Bioavailability of Antidepressants. <i>Psychopathology</i> , 1986, 19, 79-84.	1.5	6
182	Very Long Half-Life of Paroxetine Following Intoxication in an Extensive Cytochrome P4502D6 Metabolizer. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 567-569.	2.0	6
183	Mirtazapine Enantiomers in Blood and Cerebrospinal Fluid. <i>Neuropsychobiology</i> , 2006, 54, 179-181.	1.9	6
184	Effect of the NMDA-Receptor Antagonist Dextromethorphan in Infant Rat Pneumococcal Meningitis. <i>Current Drug Metabolism</i> , 2008, 9, 83-88.	1.2	6
185	Pharmakokinetik, Pharmakogenetik und therapeutisches Drug Monitoring. , 2012, , 441-464.		6
186	Quality Control of Amitriptyline and Nortriptyline Plasma Level Assessments. <i>Pharmacopsychiatry</i> , 1982, 15, 156-160.	3.3	5
187	Transport Systems and Enzymes Involved in the Metamorphosis of Tryptophan into Serotonin. <i>Pharmacopsychiatry</i> , 1985, 18, 188-192.	3.3	5
188	Lithium Augmentation in Venlafaxine-Refractory Depression. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 242-243.	1.4	5
189	Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. <i>Journal of Psychopharmacology</i> , 2004, 18, 559-566.	4.0	5
190	Clinical Relevance of TDM of SSRIs. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 716-717.	2.0	5
191	Pharmakokinetische Aspekte der Therapieresistenz mit Antidepressiva. , 1990, , 85-98.		5
192	Metabolism of 5-hydroxytryptophan-14c after intracisternal injection with and without the influence of drugs in the rat brain. <i>Psychopharmacology</i> , 1975, 45, 39-45.	3.1	4
193	Insulin coma therapy: Decrease of plasma tryptophan in man. <i>Journal of Neural Transmission</i> , 1976, 39, 309-313.	2.8	4
194	Clozapine as an alternative treatment for neuroleptic-induced gynecomastia. <i>American Journal of Psychiatry</i> , 1991, 148, 392a-393.	7.2	4
195	Vulnerability to fluoxetine-induced indifference syndrome among opiate addicts: A case report. <i>Biological Psychiatry</i> , 1995, 38, 404-406.	1.3	4
196	Pharmacogenetics of chiral psychotropic drugs. , 2002, , 181-214.		4
197	Disposition of venlafaxine enantiomers in rats with hepatic encephalopathy after chronic drug treatment. <i>Chirality</i> , 2002, 14, 347-350.	2.6	4
198	Flupentixol: relevance of stereoselective therapeutic drug monitoring. <i>Psychopharmacology</i> , 2012, 221, 719-720.	3.1	4

#	ARTICLE	IF	CITATIONS
199	Psychiatric comorbidity and additional abuse of drugs in maintenance treatment with l- and d,l-methadone. <i>World Journal of Biological Psychiatry</i> , 0, , 1-10.	2.6	4
200	Prescribing practices in German and Swiss psychiatric university and in non-university hospitals: national differences. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2005, 43, 339-349.	0.6	4
201	ANTIDEPRESSANT TREATMENT BEFORE HOSPITALIZATION FOR MAJOR DEPRESSION: OFTEN PRESCRIBED, OFTEN UNDERTITRATED. <i>Pharmacological Research</i> , 1997, 35, 33-36.	7.1	3
202	Pharmacovigilance in psychiatry: pharmacogenetic tests and therapeutic drug monitoring are promising tools. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 183-185.	3.1	3
203	Quetiapine in Adolescents with Non-Affective Psychotic Disorders: An Open-Label Trial. <i>Pharmacopsychiatry</i> , 2011, 44, 87-95.	3.3	3
204	Distribution of Tryptophan in Erythrocytes, Leukocytes and Thrombocytes, and Its Binding to Plasma Albumin. , 1979, , 165-176.		3
205	Pathologic Laughter Associated With Paroxetine Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 231.	1.4	3
206	Effects of Chronic Neuroleptic Therapy on Human PRL Secretion and Testicular Function. <i>Archives of Andrology</i> , 1981, 6, 219-228.	1.0	2
207	Hydroxylated Metabolites of Amitriptyline in Rat Brain After Repeated Administration of the Parent Drug. <i>Pharmacopsychiatry</i> , 1985, 18, 91-93.	3.3	2
208	An automated procedure for the determination of protein concentration in subcellular fractions. <i>Clinica Chimica Acta</i> , 1998, 273, 89-93.	1.1	2
209	Determination of human plasma levels of levo- $\pm$ -acetylmethadol and its metabolites by gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 805, 141-146.	2.3	2
210	Concentrações plasmáticas de paroxetina em pacientes adultos e idosos com depressão. <i>Revista De Psiquiatria Do Rio Grande Do Sul</i> , 2008, 30, 13-18.	0.3	2
211	Are Proper Names Rigid Designators?. <i>Axiomathes</i> , 2010, 20, 333-346.	0.6	2
212	Ventajas y desventajas del tratamiento de combinación con antipsicóticos. Reunión ECNP Consensus, marzo de 2008, Niza. <i>Psiquiatria Biologica</i> , 2011, 18, 55-67.	0.1	2
213	Consensus guideline for therapeutic drug monitoring in psychiatry (2004): Bibliometric analysis of citations for the period 2004-2011. <i>Nordic Journal of Psychiatry</i> , 2016, 70, 202-207.	1.3	2
214	Amitriptylinmetabolismus im depressiven Patienten: Pharmakogenetische Aspekte und Eiweißbindung im Plasma. , 1984, , 298-305.		2
215	Fluvoxamine and Perphenazine for Psychosis in Alzheimer's Disease: Pharmacokinetic Considerations. <i>Journal of Nervous and Mental Disease</i> , 2001, 189, 798-799.	1.0	2
216	CITALOPRAM IN ELDERLY DEPRESSED PATIENTS AND ADJUNCTIVE LITHIUM IN NON-RESPONDERS. <i>Clinical Neuropharmacology</i> , 1992, 15, 339B.	0.7	1

#	ARTICLE	IF	CITATIONS
217	Influence of amesergide treatment on the dextromethorphan test [letter]. <i>British Journal of Clinical Pharmacology</i> , 1994, 38, 151-152.	2.4	1
218	Characteristics of Psychotropic Drug Metabolism in Geriatric Patients. , 1998, 13, 159-170.		1
219	P01.174 Rapid remission of depression after carbamazepine augmentation of venlafaxine. <i>European Psychiatry</i> , 2000, 15, 367s-367s.	0.2	1
220	Treatment of suicide attempters prior to hospital admission. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 694-701.	4.8	1
221	Efficacy and tolerability of quetiapine in cluster B personality disorder: an open-label study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2007, 11, 123-128.	2.4	1
222	Selective Serotonin Reuptake Inhibitors in Adolescent Depression Still Controversial. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 325-326.	1.4	1
223	Creation of the Swiss group of Pharmacogenomics and personalised Therapy (SPT). <i>Drug Metabolism and Personalized Therapy</i> , 2017, 32, 173-174.	0.6	1
224	Clinical Psychopharmacology in Switzerland. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 5-8.	1.4	1
225	The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 444-447.	2.5	1
226	The fate of amitriptyline and its metabolites, taking into account their binding in plasma. , 1983, , 227-237.		1
227	Pharmakokinetik, Pharmakogenetik und therapeutisches Drug Monitoring. , 2008, , 375-397.		1
228	Citation of the AGNP consensus guidelines for therapeutic drug monitoring in psychiatry 2004 in the scientific literature 2004 to 2011. <i>Pharmacopsychiatry</i> , 2012, 45, .	3.3	1
229	Off-label Utilization of Antidepressants. <i>Acta Medica (Hradec Kralove)</i> , 2008, 51, 19-24.	0.5	1
230	The Influence of Oral Tryptophan on Cortical Evoked Responses in Normals and Schizophrenics. , 1979, , 177-188.		1
231	Genetischer Polymorphismus des Metabolismus von Neuroleptika: klinische Relevanz?. , 1993, , 99-110.		1
232	Plasma Concentrations and Cardiovascular Effects of Citalopram Enantiomers after Oral vs. Infusion Citalopram Therapy in Dextromethorphan- and Mephenytoin-Phenotyped Patients with Major Depression. <i>Therapeutic Drug Monitoring</i> , 2020, Publish Ahead of Print, 436-442.	2.0	1
233	Free and bound tryptophan in the blood of depressives. <i>Acta Vitaminologica Et Enzymologica</i> , 1975, 29, 255-61.	0.1	1
234	Purpura and ecchymosis under carbamazepine, chloral hydrate and melitracen-flupentixol. <i>European Journal of Dermatology</i> , 2008, 18, 103-4.	0.6	1

#	ARTICLE	IF	CITATIONS
235	Levomepromazine â€” a substrate of cytochrome CYP2D6?. European Neuropsychopharmacology, 1994, 4, 370.	0.7	0
236	S.03.01 Advantages and disadvantages of lithium augmentation. European Neuropsychopharmacology, 1997, 7, S82.	0.7	0
237	P.1.010 MAO-A and MAO-B differ in their stereoselective biotransformation of citalopram in human liver. European Neuropsychopharmacology, 1997, 7, S137-S138.	0.7	0
238	Correspondence. Clinica Chimica Acta, 1998, 271, 105-107.	1.1	0
239	P02.271 Pharmacokinetic drug interaction potential of risperidone as assessed by the dextromethorphan, the caffeine and the mephenytoin test. European Psychiatry, 2000, 15, 394s-395s.	0.2	0
240	Therapy with Antidepressants: Pharmacogenetic Aspects. , 2002, 21, 95-111.		0
241	Dose-Dependent Venlafaxine-Induced Hair Loss. Drug Safety, 2006, 29, 911-1010.	3.2	0
242	Psychotropic drug prescriptions in hospitalized elderly psychiatric patients: comparison with adult psychiatric patients. Psychogeriatrics, 2006, 6, 68-73.	1.2	0
243	Drug monographs on drugs which are frequently analysed in the context of Therapeutic Drug Monitoring / Arzneimittel-Monographien f¼r Medikamente, die regelmÄig im Rahmen des Therapeutic Drug Monitorings analysiert werden. Das Medizinische Laboratorium, 2006, 30, 443-452.	0.0	0
244	Problem solving in psychopharmacotherapy using pharmacokinetic and pharmacogenetic tests. European Psychiatry, 2007, 22, S96.	0.2	0
245	Therapeutic Drug Monitoring and Pharmacogenetic Tests in Pharmacovigilance - When and What?. European Psychiatry, 2009, 24, .	0.2	0
246	SPCCTDM, a Catalogue for Analysis of Therapeutic Drug Monitoring Related Contents in the Drug Prescription Information. International Journal of Knowledge Discovery in Bioinformatics, 2010, 1, 1-11.	0.8	0
247	JS01-01 - Pharmacokinetics of psychotropic drugs - keys for treatmentsâ€™ improvements. European Psychiatry, 2011, 26, 1995-1995.	0.2	0
248	Therapeutic drug monitoring of drugs for treatment of substance-related disorders. European Psychiatry, 2011, 26, 13-13.	0.2	0
249	Therapeutic Drug Monitoring in Psychiatry. Pharmacopsychiatry, 2011, 44, 193-194.	3.3	0
250	The AMSP-project: Pharmacovigilance in psychiatry - Presentation, challenges and results. European Psychiatry, 2014, 29, 663-663.	0.2	0
251	Pharmacovigilance en psychiatrieÂ: donnÃ©es rÃ©centes. European Psychiatry, 2014, 29, 661-662.	0.2	0
252	Clinical pharmacological management of polypharmacy in old age depression. European Psychiatry, 2016, 33, S39-S39.	0.2	0

#	ARTICLE	IF	CITATIONS
253	Training in Psychopharmacology-Pharmacopsychiatry for Residents in Psychiatry. <i>Mental Health and Illness Worldwide</i> , 2019, , 141-167.	0.1	0
254	About the Misleading Use of Stereodescriptors in Labeling the Stereoisomers of Milnacipran and Levomilnacipran. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 673-674.	1.4	0
255	Prescription of St John's Wort extracts: clinical risks due to differences in their hyperforin content. <i>Minerva Psychiatry</i> , 2021, 62, .	0.3	0
256	Pharmakokinetik und therapeutisches Monitoring von Antidepressiva. , 2002, , 37-50.		0
257	Influence of metabolic processes on course and treatment of opioid-dependence. <i>Pharmacopsychiatry</i> , 2003, 36, .	3.3	0
258	Clinical Relevance of Citalopram (CIT) Plasma and Cerebrospinal Fluid (CSF) Concentrations: Impact with CSF Monoamine Metabolites. <i>Pharmacopsychiatry</i> , 2005, 38, .	3.3	0
259	Metabolism of Citalopram by MAO: Pharmacogenetic and Kinetic Animal Studies. <i>Pharmacopsychiatry</i> , 2005, 38, .	3.3	0
260	Plasma-CSF Concentrations Relationship of Psychotropic Drugs. <i>Pharmacopsychiatry</i> , 2005, 38, .	3.3	0
261	Follow-Up of a Pharmacovigilance Study in Psychiatry Involving TDM and Pharmacogenetic Testing. <i>Pharmacopsychiatry</i> , 2005, 38, .	3.3	0
262	Severe Bruising as an Adverse Event: Chocolate or Fluvoxamine? Case Report. <i>Pharmacopsychiatry</i> , 2005, 38, .	3.3	0
263	Optimisation of psychopharmacotherapy: Clinical relevance of pharmacogenetic tests and therapeutic drug monitoring. <i>Pharmacopsychiatry</i> , 2005, 38, .	3.3	0
264	Pharmacogenetics of Clozapine: In Vivo Role of Cytochrome P450 Isoforms and P-Glycoprotein. <i>Pharmacopsychiatry</i> , 2008, 41, .	3.3	0
265	Text Analysis and Drug Analysis: Therapeutic Drug Monitoring in the Prescription Information. <i>Pharmacopsychiatry</i> , 2008, 41, .	3.3	0
266	Metabolism of Psychotropic Drugs in the Human Brain: Significance for Therapeutic Drug Monitoring?. <i>Pharmacopsychiatry</i> , 2008, 41, .	3.3	0
267	The AGNP-TDM Expert Consensus Guidelines 2004: A Promising Start!. <i>Pharmacopsychiatry</i> , 2008, 41, .	3.3	0
268	TDMplus: The Combination of TDM, Check for Drug Interactions and Genotyping. <i>Pharmacopsychiatry</i> , 2008, 41, .	3.3	0
269	Clinical effectiveness, pharmacokinetics and pharmacogenetics of mirtazapine in depression. <i>Pharmacopsychiatry</i> , 2012, 45, .	3.3	0
270	Matched case-control study: therapeutic drug monitoring in pharmacovigilance. <i>Pharmacopsychiatry</i> , 2012, 45, .	3.3	0



#	ARTICLE	IF	CITATIONS
271	Allgemeine Grundlagen der Pharmakokinetik und Pharmakodynamik. , 1992, , 273-286.		0
272	Pharmakokinetische und pharmakodynamische Interaktionen zwischen trizyklischen und serotonergen Antidepressiva im Verlauf einer Behandlung. , 1993, , 664-670.		0
273	Klinische Relevanz pharmakogenetischer PhÄnotypisierungen. , 1993, , 658-663.		0
274	Implementation of Therapeutic Drug Monitoring and Pharmacogenetic Tests in Psychiatry: How About ABCB1?. Journal of Bioequivalence & Bioavailability, 2018, 10, .	0.1	0
275	Training in Psychopharmacology-Pharmacopsychiatry for Residents in Psychiatry. Mental Health and Illness Worldwide, 2018, , 1-28.	0.1	0
276	4 Slow-drop infusion versus oral administration of citalopram: Comparison of plasma concentrations of the enantiomers of citalopram and its metabolites. , 2020, 53, .		0
277	SPCCTDM, a Catalogue for Analysis of Therapeutic Drug Monitoring Related Contents. , 0, , 319-328.		0
278	Pharmacotherapy of Personality Disorders. , 2022, , 1-18.		0
279	Gerd Laux, Walter E. MÄ¼ller (Herausgeber): Psychopharmakologie und Psychopharmakotherapie kompakt. Weiterbildungs-Curriculum zum Facharzt fÄ¼r Psychiatrie und Psychotherapie. Swiss Archives of Neurology, Psychiatry and Psychotherapy, 2021, 172, .	0.1	0
280	Determination of compliance with riboflavin in an antidepressive therapy. Arzneimittelforschung, 1985, 35, 536-8.	0.4	0
281	Effect of calcitonin on free and total plasma tryptophan in human. Acta Vitaminologica Et Enzymologica, 1980, 2, 6-8.	0.1	0
282	Therapeutic drug monitoring of antidepressants–clinical aspects. Journal of Neural Transmission Supplementum, 2007, , 261-7.	0.5	0